Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Completed · Phase 2

Conditions studied: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, Leukemia, Prolymphocytic

In brief

The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).

Key facts

Study ID

NCT01419691

Run by

University of Kansas Medical Center

People needed

15

Starts

2011-09-01

Expected to finish

2015-09-01

Last updated by the study team

2016-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically confirmed B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia arising from CLL/SLL or Richter's transformation according to WHO criteria who require therapy based on the 2008 revised IWCLL criteria.
• Relapsed or refractory disease after receiving at least 1 prior therapy for CLL
• At least 18 years old; ECOG status of 1 or less; life expectancy 2 months or greater
• Adequate organ and marrow function (total bilirubin less than 1.5x IULN; ALT less than 2x IULN; serum creatinine less than 1.5x ULN)

You may not qualify if…

• have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to entering study
• have not recovered from AEs due to agents administered more than 4 weeks prior
• receiving any other investigational agent
• known second malignancy that limits survival to less than 2 years
• known HIV positive
• uncontrolled intercurrent illness
• pregnant or breastfeeding

Where it is running

• University of Kansas Cancer Center — Westwood, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.